Ana obtained her degree on Veterinary Medicine from the University of Murcia in 2013. Shortly after her degree Ana moved to the UK and did her PhD in Salford University on the epidemiology and genetic diversity of Toxoplasma gondii in Mexico. After her PhD she was appointed as Research Fellow at the Roslin Institute where she worked on molecular characterisation and development of novel diagnostic methods for porcine viral and bacterial diseases.
Ana joined LSTM in 2019 as a Post-Doctoral Research Associate to work on novel and Point-of-Care (POC) diagnostics for Crimean-Congo Hemorrhagic Fever (CCHF) and molecular diagnosis of AMR markers. In 2021 Ana was promoted to Senior Post-Doctoral Research Associate and Project Manager in Diagnostics. Ana is interested in improving diagnostics for High Consequence Infectious Diseases and Emerging Diseases that have the potential to cause epidemics such as SARS-CoV-2, CCHF, Ebola and Lassa Fever. She leads diagnostic clinical and analytical evaluations for COVID-19 and the development of POC diagnostics for CCHF and Lassa Fever.
Ana lectures on LIVE361 and Translational Research in Global Health (MRes)
Other relevant expertise, professional memberships, awards
Ana is one of the diagnostics leads for LSTM’s Centre for Drugs and Diagnostics (CDD), she sits on the management committee of iiDiagnostics and is the project lead of the COVID-19 diagnostic portfolio for iiCON. Ana is an active member of the Clinical Reference Group at LSTM and Deputy representative for TDB for the Health and Safety Oversight Committee (HSOC).
Research grants and contracts
• The Pandemic Institute Emerging Threats Funding Call 2021-2023: Co-investigator (Co-I). Rapid development of an antigen lateral flow diagnostic test for Monkeypox virus. £200,000.
• Foundation of New Diagnostics (FIND) 2021-2023: Principal Investigator (PI). Implementation of accurate diagnostics for COVID-19 in point of care settings. £510,000.
• iTPA Welcome Trust 2021-2022: PI. Rapid detection of Viral Haemorrhagic Fevers: novel antigen detection systems to accurately diagnose and differentiate Lassa Fever and Ebola infections: £38,000.
• Director’s Catalyst Fund 2021-2022: PI. Accelerating diagnosis of Crimean Congo Haemorrhagic Fever (CCHF) through simultaneous detection of viral antigens and IgM: £46,221.
• Bill & Melinda Gates foundation 2021-2023: PI to evaluate digital diagnostic readers for Malaria RDTs: £31,270.
• MRC Confidence in Concept (CIC) 2021-2022: Co-I on the development of monoclonal antibodies towards an antigen test for CCHF: £47,268.
• FIND 2020-2021: Co-I to evaluate accurate diagnostics for COVID-19: £250,000.
• Welcome Trust 2020-2021: Co-I. Detecting and excluding COVID-19 at the point of need: £480,000.
• Public Health Rapid Support Team (UK PHRST): Co-investigator (Co-I) Rapid response molecular diagnostics for Crimean-Congo Haemorrhagic Fever: £49,320.